Par Pharma Begins Shipping Generic Atacand HCT

Loading...
Loading...
Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca
AZN
to distribute the authorized generic version of AstraZeneca's Atacand HCT^® (candesartan cilexetil/hydrochlorothiazide). Par has begun shipping 16/12.5 mg, 32/12.5 mg and 32/25 mg strengths of candesartan cilexetil/ hydrochlorothiazide tablets. According to IMS Health data, annual U.S. sales of Atacand HCT^® are approximately $61 million.
Posted In: News
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...